Picture of Imac Holdings logo

BACK Imac Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-42.08%
3m-94.27%
6m-96.74%
1yr-99.27%
Volume Change (%)
10d/3m-97.53%
Price vs... (%)
52w High-99.12%
50d MA-87.98%
200d MA-96.21%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-7804.68%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Imac Holdings EPS forecast chart

Profile Summary

IMAC Holdings, Inc. is a clinical research and commercialization company. The Company is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The Company is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The Company is also engaged in providing the precision medicine business. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    December 31st, 2024
    Incorporated
    May 23rd, 2018
    Public Since
    February 13th, 2019
    No. of Shareholders
    63
    No. of Employees
    15
    Sector
    Healthcare Providers & Services
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    3,784,966

    BACK Share Price Performance

    Upcoming Events for BACK

    Q1 2025 IMAC Holdings Inc Earnings Release

    Q2 2025 IMAC Holdings Inc Earnings Release

    IMAC Holdings Inc Annual Shareholders Meeting

    Similar to BACK

    Picture of 4Cable TV International logo

    4Cable TV International

    us flag iconPink Sheets on Nasdaq

    Picture of Abattis Bioceuticals logo

    Abattis Bioceuticals

    us flag iconPink Sheets on Nasdaq

    Picture of Accelera Innovations logo

    Accelera Innovations

    us flag iconPink Sheets on Nasdaq

    Picture of Quantum Medical Transport logo

    Quantum Medical Transport

    us flag iconPink Sheets on Nasdaq

    FAQ